Cardinal Health shares rise after CVS distribution deal extension clears contract risk
Cardinal Health gains on Thursday after extending a key distribution relationship with CVS Health, easing a major uncertainty for investors as markets navigate higher Treasury yields and shifting rate expectations. The agreement runs through June 30, 2032, and the company keeps its fiscal 2027 adjusted EPS growth guidance and long-term earnings outlook unchanged.
Highlights
- Cardinal Health extends its CVS Health distribution agreement to June 30, 2032, lifting shares 3% to 4% and removing contract risk.
- Cardinal Health reaffirms fiscal 2027 adjusted EPS growth guidance of 13% to 15% and long-term growth of 12% to 14%, indicating stable CVS terms.
- McKesson also renews its CVS deal, gaining more than Cardinal as it faced higher CVS contract risk, with Bank of America calling both extensions clearing events.
Contract extension supports earnings outlook
As reported by CNBC Investing Club with Jim Cramer, Cardinal Health says it has entered a binding letter of intent to extend its existing distribution agreement with CVS Health through June 30, 2032. The stock is up about 3% to 4% on Thursday, alongside McKesson, after the updates remove a key overhang tied to CVS contract negotiations.Cardinal Health also reaffirms its fiscal 2027 adjusted EPS guidance for 13% to 15% growth and its long-term adjusted EPS growth guidance for 12% to 14%. That suggests the economics of the CVS relationship do not materially change, despite investor concern that CVS could press for tougher terms.
McKesson announces a similar distribution agreement with CVS. Bank of America describes the extensions as a clearing event for both stocks, while McKesson posts a slightly larger gain because it had faced greater risk of losing the CVS business.
Broader market and sector implications
Thursday trading remains volatile as the S&P 500 trims earlier losses after Treasury yields retreat from session highs. The 10-year Treasury yield had reached its highest level since April 2022 before bond prices rebound, while the probability of a 25-basis-point rate increase at the Federal Reserve's meeting later this month falls to about 29%, from 37% a day earlier and 68% a week ago, according to the CME FedWatch tool.For Cardinal Health, the contract resolution may shift investor attention back to the company's defensive profile, double-digit growth record and limited exposure to the economy and interest rates. The move also comes as the healthcare distribution sector remains in focus, with CVS relationships carrying significant implications for revenue visibility and long-term profit expectations.
Our earlier coverage of the Federal Reserve’s October rate outlook explained how senior policymakers urged patience after September’s move, leading markets to scale back expectations for another near-term hike. We noted that rising U.S. Treasury yields were tightening financial conditions and reshaping investor positioning across bonds and equities.